Powered by

GNW: Biogen Announces Agreement to Acquire Nightstar Therapeutics to Establish

Mar 04, 2019 - AWP OTS (Original Text Service)
Mergers and Acquisitions

Clinical Pipeline of Gene Therapy Candidates in Ophthalmology

Biogen to acquire Nightstar Therapeutics for $25.50 per share

Nightstar Therapeutics is a gene therapy company focused on developing novel treatments for patients suffering from rare inherited retinal diseases that would otherwise lead to blindness

Nightstar has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs

Lead asset NSR-REP1 is in Phase 3 development for cho...